Alpha Teknova Inc (TKNO)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Alpha Teknova Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.

Alpha Teknova produces critical reagents for discovery, development, and commercialization of therapies, vaccines, and diagnostics. The company serves pharmaceutical and biotechnology companies, contract manufacturers, diagnostics providers, and research institutions through three primary product types: pre-poured media plates, liquid microbial culture media and supplements, and molecular biology reagents. Its offerings span research-use and GMP-grade custom formulations.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Alpha Teknova Inc stock.

Our verdict on TKNO

Overvalued: intrinsic value $0.60 per share, market price $7.65, margin of safety -1177.8% (as of 2026-11-17).

A 1.0x revenue multiple, discounted for its losses, values the shares at $0.60; the price of $7.65 is 1178% above that value.

ETFs with the most weight in TKNO

15 more funds hold it; the full list is part of the paid plan.

More on TKNO

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than TKNO in Drug Manufacturers - Specialty & Generic

32 more in this industry show a wider margin of safety.

Is TKNO undervalued or overvalued?

TKNO is overvalued (as of the 2026-11-17 close). A 1.0x revenue multiple, discounted for its losses, values the shares at $0.60; the price of $7.65 is 1178% above that value.

What is the intrinsic value of TKNO?

$0.60 per share (as of the 2026-11-17 close), against a market price of $7.65. That is a margin of safety of -1177.8%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.